Novo Nordisk A-S

How Novo Nordisk’s new oral Wegovy could reshape the obesity‑drug market amid tighter FDA scrutiny, fierce competition, and potential M&A moves.

Novo Nordisk faces scrutiny over low tax‑transparency scores and emerging neurological risks linked to GLP‑1 drugs, urging better disclosure and safety research.

Discover how Novo Nordisk’s Wegovy approval for children in India and robust U.S. payer relationships strengthen its GLP‑1 market position, boosting access, pricing and investor confidence.

Discover how Novo Nordisk is mastering reimbursement hurdles, scaling production, and expanding its obesity and metabolic portfolio for sustained growth.

Novo Nordisk bolsters its obesity‑treatment strategy by expanding digital sales, advancing Wegovy and multi‑target UBT 251, while safeguarding shareholder value through a robust buy‑back program.

Discover how Novo Nordisk’s share‑buyback, Brazil expansion, and new POSEIDON findings drive EPS growth, market share shifts, and broader CKD/heart‑risk therapies.

Explore how Novo Nordisk’s new single‑dose pen and oral tablet for weight‑management could boost EU market share, margin, and ESG appeal amid rising competition.

Discover how Novo Nordisk’s partnership with Abbott India and FDA approval of Sogroya broaden its diabetes, obesity and pediatric therapy reach—boosting global market growth.

Novo Nordisk’s latest moves—Vivtex licensing for oral diabetes therapy, expanded Sogroya approval, and the Indian Extensior launch—reshape its growth strategy, offering new revenue streams amid rising competition and regulatory shifts.

New partnership with Vivtex could bring oral biologics for obesity and type 2 diabetes, boosting Novo Nordisk’s pipeline while maintaining strong fundamentals and dividend policy.